Your browser doesn't support javascript.

Biblioteca Virtual em Saúde


Home > Pesquisa > ()
Imprimir Exportar

Formato de exportação:


Adicionar mais destinatários
| |

Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Rossignol, Patrick; Agarwal, Rajiv; Canaud, Bernard; Charney, Alan; Chatellier, Gilles; Craig, Jonathan C; Cushman, William C; Gansevoort, Ronald T; Fellström, Bengt; Garza, Dahlia; Guzman, Nicolas; Holtkamp, Frank A; London, Gerard M; Massy, Ziad A; Mebazaa, Alexandre; Mol, Peter G M; Pfeffer, Marc A; Rosenberg, Yves; Ruilope, Luis M; Seltzer, Jonathan; Shah, Amil M; Shah, Salim; Singh, Bhupinder; Stefánsson, Bergur V; Stockbridge, Norman; Stough, Wendy Gattis; Thygesen, Kristian; Walsh, Michael; Wanner, Christoph; Warnock, David G; Wilcox, Christopher S; Wittes, Janet; Pitt, Bertram; Thompson, Aliza; Zannad, Faiez.
Eur Heart J; 2017 Apr 18.
Artigo em Inglês | MEDLINE | ID: mdl-28431138
Although cardiovascular disease is a major health burden for patients with chronic kidney disease, most cardiovascular outcome trials have excluded patients with advanced chronic kidney disease. Moreover, the major cardiovascular outcome trials that have been conducted in patients with end-stage renal disease have not demonstrated a treatment benefit. Thus, clinicians have limited evidence to guide the management of cardiovascular disease in patients with chronic kidney disease, particularly those on dialysis. Several factors contribute to both the paucity of trials and the apparent lack of observed treatment effect in completed studies. Challenges associated with conducting trials in this population include patient heterogeneity, complexity of renal pathophysiology and its interaction with cardiovascular disease, and competing risks for death. The Investigator Network Initiative Cardiovascular and Renal Clinical Trialists (INI-CRCT), an international organization of academic cardiovascular and renal clinical trialists, held a meeting of regulators and experts in nephrology, cardiology, and clinical trial methodology. The group identified several research priorities, summarized in this paper, that should be pursued to advance the field towards achieving improved cardiovascular outcomes for these patients. Cardiovascular and renal clinical trialists must partner to address the uncertainties in the field through collaborative research and design clinical trials that reflect the specific needs of the chronic and end-stage kidney disease populations, with the shared goal of generating robust evidence to guide the management of cardiovascular disease in patients with kidney disease.
Selo DaSilva